Senior Scientist - Bioanalytical

Senior Scientist

• Bioanalytical Protagonist Therapeutics
• 4.0 Newark, CA Job Details $140,000
• $160,000 a year 21 hours ago Qualifications Laboratory equipment maintenance Standard Operating Procedures (SOPs) implementation Biochemical laboratory techniques Chemical separation processes Laboratory standard operating procedures Spectrometer Cross-functional collaboration Standard operating procedures (SOPs) Cross-functional communication Data analysis software Full Job Description Senior Scientist•Bioanalytical We are seeking a Senior Scientist in the Bioanalytical department.

The qualified candidate will be a critical member of the group and work closely with our established team developing and optimizing analytical methods and performing bioanalytical work to screen chemical entities for new drug candidates. This is an exceptional opportunity to work with a core discovery group within a successful biopharmaceutical company and bring drugs from ideas to the clinic. Responsibilities include, but are not limited to: Operate and maintain analytical instrumentation such as HPLC, mass spectrometer, and other lab equipment Prepare reagents, calibration standards, QCs and standard curves, and samples for analysis Perform, optimize, develop, and execute new and existing analytical methods Perform analytical assays (i.e., ELISA) to support PD and efficacy studies Work with Bioanalytical team to ensure adequate supplies of consumables and reagents Possess technical and scientific understanding of bioanalytical assays and experimental design to support the development Keep excellent experimental records Effectively communicate results to the Bioanalytical team and cross-functionally Follow and maintain laboratory safety protocol and health-conscious environment in the workplace.

Position Requirements & Experience:

MS in chemistry, analytical chemistry, biochemistry, bioengineering, or related fields with 5+ years of relevant industry or academic experience or BS with 10+ years of experience. Previous experience operating and maintaining analytical instrumentation, including HPLC, mass spectrometer, spectrophotometers, and data analysis software Understanding and experience with the fundamentals of chromatography and analytical separations Proven ability to follow SOPs and optimize existing methods Time management and organizational skills with attention to detail Thrive in a fluid, dynamic, and fast-paced environment Able to collaborate effectively within multi-disciplinary teams Effectively communicate results to the Bioanalytical team, across various functional areas, and project team The base pay range for this position at commencement of employment is expected to be between $140K and $160K / year; however, base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience. Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. The Company's proprietary peptide technology platform enables de novo discovery of peptide therapeutics . Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra) is approved in the U.S. for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor (IL-23R) licensed to Janssen Biotech, Inc.,a Johnson & Johnson company. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. An NDA for rusfertide, a first-in-class hepcidin mimetic peptide that is being co-developed with Takeda Pharmaceuticals pursuant to a worldwide license and collaboration agreement entered in 2024, is under priority review with the FDA. Protagonist holds an option to co-commercialize rusfertide in the U.S. through a 50/50 profit and loss share structure or can opt-out of this structure. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets including an oral IL-17 peptide antagonist, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs. More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.